CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0737 (clinicaltrials.gov NCT No: NCT01787487)
Title:
EVALUATION OF RUXOLITINIB AND AZACYTIDINE COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME/ MYELOPROLIFERATIVE NEOPLASM
Principal Investigator:Naval Daver
Treatment Agent:Ruxolitinib
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
ruxolitinib and azacytidine can help to control myelofibrosis and
myelodysplastic syndrome/ myeloproliferative neoplasm.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Ruxolitinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Incyte
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naval Daver
Dept:Leukemia
For Clinical Trial Enrollment:713-794-4392
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults